ApexBio (1733) reported revenue of NT$133.9 million for Oct 2026, -13.9% year on year and -3.9% from the previous month. Revenue for Jan–Oct 2026 was NT$1.55 billion (-6.6% year on year).
In Oct 2026, it ranked No. 61 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$133.9 million | -13.9% | -3.9% |
| Sep 2026 | NT$139.4 million | -23.0% | -4.8% |
| Aug 2026 | NT$146.4 million | -0.4% | +2.7% |
| Jul 2026 | NT$142.6 million | +30.5% | -18.0% |
| Jun 2026 | NT$174 million | +20.1% | +19.4% |
| May 2026 | NT$145.7 million | -18.1% | -3.6% |
| Apr 2026 | NT$151 million | -19.3% | +6.8% |
| Mar 2026 | NT$141.4 million | -24.1% | -20.7% |
| Feb 2026 | NT$178.3 million | -12.0% | -10.9% |
| Jan 2026 | NT$200.1 million | +17.9% | +39.9% |
| Dec 2025 | NT$143 million | -16.1% | +1.8% |
| Nov 2025 | NT$140.5 million | +10.9% | -9.7% |
| Oct 2025 | NT$155.5 million | -0.8% | -14.1% |
| Sep 2025 | NT$181.1 million | -2.9% | +23.3% |
| Aug 2025 | NT$146.9 million | -19.9% | +34.5% |
| Jul 2025 | NT$109.2 million | -21.9% | -24.6% |
| Jun 2025 | NT$144.9 million | -5.2% | -18.5% |
| May 2025 | NT$177.8 million | +22.4% | -5.0% |
| Apr 2025 | NT$187.3 million | +33.8% | +0.5% |
| Mar 2025 | NT$186.4 million | +43.7% | -8.0% |
| Feb 2025 | NT$202.7 million | +56.6% | +19.4% |
| Jan 2025 | NT$169.7 million | -11.4% | -0.5% |
| Dec 2024 | NT$170.5 million | +55.4% | +34.6% |
| Nov 2024 | NT$126.7 million | -23.8% | -19.2% |
| Oct 2024 | NT$156.7 million | +16.9% | -15.9% |
Jan–Oct 2026 cumulative: NT$1.55 billion (-6.6% YoY)
Other Biotech & Medical companies
Compare with peers: ApexBio vs PEC / ApexBio vs Lotus Pharm / ApexBio vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16